bioRxivCancer BiologyPreprint
Whole genome sequencing provides evidence of two biologically and clinically distinct entities of asymptomatic monoclonal gammopathies: progressive versus stable myeloma precursor condition
B. Oben, G. Froyen, K. H. Maclachlan, D. Leongamornlert, F. Abascal, B. Zheng-Lin, V. Yellapantula, A. Derkach, E. Geerdens, B. T. Diamond, I. Arijs, B. Maes, K. Vanhees, M. Hultcrantz, E. E. Manasanch, D. Kazandjian, A. Dogan, Y. Zhang, A. Mikulasova, B. Walker, G. Morgan, P. J. Campbell, O. Landgren, J.-L. Rummens, N. Bolli, F. Maura
Abstract
Multiple myeloma (MM) is consistently preceded by precursor conditions recognized clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). We interrogate, for the first time, the whole genome sequence (WGS) profile of 18 MGUS and compare them with those from 14 SMMs and 80 MMs. We show that cases with a non-progressing, clinically stable myeloma precursor condition (n=15) are characterized by later initiation in the patients life and by the absence of myeloma defining genomic events including: chromothripsis, templated insertions, mutations in driver genes, aneuploidy, and canonical APOBEC mutational activity. This data provides evidence that WGS can be used to recognize two biologically and clinically distinct myeloma precursor entities that are either progressive or stable.
- organism: human
- assay: whole-genome sequencing
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Linked-read whole-genome sequencing resolves common and private structural variants in multiple myeloma
Lucía Peña‐Pérez, Nicolai Sebastian Frengen, … Robert Månsson·Blood AdvancesPeer-reviewed·Jun 8, 2022
- Copy number signatures predict chromothripsis and associate with poor clinical outcomes in patients with newly diagnosed multiple myeloma
Kylee H. Maclachlan, Even Holth Rustad, … Francesco Maura·Nature CommunicationsPeer-reviewed·Aug 27, 2021
- Impact of rare structural variant events in newly diagnosed multiple myeloma
M. Chojnacka, B. T. Diamond, … F. Maura·bioRxiv·Jan 3, 2023
- Direct mass spectrometry-based detection and antibody sequencing of Monoclonal Gammopathy of Undetermined Significance from patient serum - a case study.
W. Peng, M. A. den Boer, … J. Snijder·bioRxiv·May 22, 2023
- The Vk*MYC Mouse Model recapitulates human multiple myeloma evolution and genomic diversity
F. MAURA, D. G. Coffey, … M. Chesi·bioRxiv·Jul 25, 2023
- Genomic characterization of patient derived xenograft models of multiple myeloma reveals selection of multiple pre-existing high risk clones
Nathan J. Becker, Enze Liu, … Brian A. Walker·bioRxiv·Oct 16, 2026